Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2012:2012:931636.
doi: 10.1155/2012/931636. Epub 2011 Aug 22.

Chinese herbal formula xiao yao san for treatment of depression: a systematic review of randomized controlled trials

Yuqing Zhang  1 , Mei Han, Zhijun Liu, Jie Wang, Qingyong He, Jianping Liu
Affiliations

Chinese herbal formula xiao yao san for treatment of depression: a systematic review of randomized controlled trials

Yuqing Zhang et al. Evid Based Complement Alternat Med. 2012.

Abstract

Objectives. To assess the beneficial and adverse effects of Xiaoyaosan for depression. Search Strategy. Electronic databases were searched until December 2009. Inclusion Criteria. We included randomized clinical trials testing Xiaoyaosan against placebo, antidepressants, or combined with antidepressants against antidepressants alone. Data Extraction and Analyses. Study selection, data extraction, quality assessment, and data analyses were conducted according to the Cochrane standards. Results. 26 randomized trials (involving 1837 patients) were included and the methodological quality was evaluated as generally low. The pooled results showed that Xiaoyaosan combined with antidepressants was more effective in comprehensive effect, the score of HAMD and the score of SDS compared with antidepressants alone. Xiaoyaosan was superior to antidepressants for the score of HAMD. However, Xiaoyaosan was not different from placebo for the score of SDS. There was no adverse effects reported in the trials from Xiaoyaosan. Conclusions. Xiaoyaosan appears to be effective on improving symptoms in patients with depression. However, due to poor methodological quality in the majority of included trials, the potential benefit from Xiaoyaosan need to be confirmed in rigorous trials and the design and reporting of trials should follow international standards.

PubMed Disclaimer

Figures

Figure 1
Figure 1
Study selection process.
Figure 2
Figure 2
Funnel plot.
Figure 3
Figure 3
Side effect of including studies (“xiaoyaosan” versus antidepressants).
See this image and copyright information in PMC

References

    1. Jablensky A, Schwarz R, Tomov TL. WHO collaborative study on impairments and disabilities associated with schizophrenic disorder. Acta Psychiatrica Scandinavica. 1980;62(supplement 285):152S–159S.
    1. Jablensky A, Schwarz R, Tomov TL. WHO collaborative study on impairments and disabilities associated with schizophrenic disorder. In: Murray CJL, Lopez AD, editors. Summary of the Global Burden of Disease. Cambridge, Mass, USA: Harvard University Press; 1996.
    1. Spitzer RL, Kroenke K, Linzer M, et al. Health-related quality of life in primary care patients with mental disorders: results from the PRIME-MD 1000 study. Journal of the American Medical Association. 1995;274(19):1511–1517. - PubMed
    1. Chong W. Depression sufferers grow in China. China daily, http://www.chinadaily.com.cn/english/doc/2005-03/08/content_422677.htm.
    1. Depression patients exceeding 26 million in China. http://english.peopledaily.com.cn/200312/19/eng20031219_130779.shtml.

LinkOut - more resources